Shares surged as GE HealthCare delivered a Q2 that crushed expectations on nearly every front, posting the kind of orders growth that suggests hospitals aren't done spending. But a departing CFO and thin cash flow complicate the celebration, raising a question shareholders can't ignore: Is this a turning point or a sugar high?
An Earnings Beat That Blindsided the Street
Revenue hit $5.30 billion, beating analyst estimates of $5.27 billion, while adjusted EPS of $1.13 topped the $1.04 consensus by 9.1%. That EPS figure is especially notable: in Q1, the company missed consensus by $0.08 , so the rebound signals improved execution, not just low expectations. Both diluted EPS of $1.24 and adjusted EPS benefited from tariff refunds and a lower tax rate — one-time boosts investors should weigh carefully.
Record Orders Signal Hospitals Are Still Buying
Organic orders surged 11.1%, producing a book-to-bill ratio of 1.15x — meaning for every dollar of revenue shipped, $1.15 in new orders came in — and pushing backlog to a record $23.9 billion. That's a massive jump from Q1's tepid 1.1% organic orders growth and $21.8 billion backlog . CEO Peter Arduini noted "record orders and backlog... with orders growth across every segment." A backlog this large essentially pre-books more than four quarters of revenue, giving shareholders strong visibility into future sales.
The CFO Exit and Cash Flow Are the Fine Print
CFO Jay Saccaro will step down August 14 , with Controller George Newcomb named interim CFO. Losing a finance chief mid-stride rattles investors even when results are strong. Meanwhile, Q2 free cash flow was just $68 million against $10.1 billion in debt — a razor-thin 1.3% margin. Management reaffirmed full-year free cash flow guidance of roughly $1.6 billion , implying a heavy second-half cash conversion that remains unproven.
A Weaker Spot Lurks Inside the Portfolio
Advanced imaging and pharmaceutical diagnostics grew strongly, but Patient Care Solutions declined and is under strategic review — corporate speak for a possible sale or restructuring. China's market recovery has remained choppy, and lingering margin pressure in patient-care equipment could temper profitability if hospital budgets tighten. Adjusted EBIT margin of 14.2% actually slipped from 14.6% a year ago , a reminder that revenue growth hasn't yet translated into fatter profits.
At $72, GEHC trades at roughly 15x its midpoint full-year EPS guidance of $4.90. The record backlog justifies optimism, but investors are paying today for cash flow that still needs to show up tomorrow.